Indications
Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1).
Composition
- Active substance
- Eladocagene exuparvovec
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Upstaza
- Active substance
- Eladocagene exuparvovec
- ATC code
- A16AB26
- Therapeutic area
- Amino Acid Metabolism, Inborn Errors
- Marketing authorisation holder
- PTC Therapeutics International Limited